Halozyme Therapeutics (NASDAQ:HALO) Releases FY23 Earnings Guidance : vimarsana.com

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) updated its FY23 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $2.77-2.80 for the period, compared to the consensus estimate of $2.66. The company issued revenue guidance of $827-832 million, compared to the consensus revenue estimate of $834.81 million. Analysts Set New Price […]

Related Keywords

United States , Hong Kong , Switzerland , Belgium , Japan , Ireland , Michaelj Labarre , , Halozyme Therapeutics Inc , Advisory Services Network , Acadian Asset Management , Morgan Stanley , Hong Kong Ltd , Belpointe Asset Management , Securities Exchange Commission , Harbour Investments Inc , Halozyme Therapeutics , Get Free Report , Moderate Buy , Exchange Commission , Services Network , Asset Management , Kong Ltd , Halozyme Therapeutics Daily , Nasdaq Halo , Halo , Medical , 40637h10 , Guidance , Earnings , Preannouncement ,